Clin Cancer Res: New antibody-drug coupling agent SAR408701 treats the activity of CEACAM5-positive endoskin tumors.

Cancer embryo antigen-related cell adhesion molecule 5 (CEACAM5) is a glycoprotein that is restricted in normal adult tissue but has been expressed in gastrointestinal, genitourinal, respiratory and breast cancers.
, CEACAM5 is an attractive target based on antibody therapy, designed to selectively deliver cytotoxic drugs to certain endotour tumors.
In this study, researchers reported data on a pre-clinical trial of a new antibody-drug coupled agent (ADC) - SAR408701, made up of anti-CEACAM5 antibodies (SAR408377) and maytansinoid preparation DM4.
researchers tested the specificity and affinity of SAR408701 pairs of ceACAM5 in humans and crab-eating monkeys.
cytotoxicity of SAR408701 was also evaluated in tumor cell line and CEACAM5-positive tumor patients in patients with heterogeneity transplantation.
SAR408701 selectively combines CEACAM5 with that of crab-eating monkeys, and has similar Kd values (0.017 nM and 0.024 nM) between the two species.
in vitro and in vivo assessments showed that SAR408701 had cytototoxic activity, and that both single and repeated dosing could work in the body.
single dose SAR408701 can induce a significant increase in the expression of phosphate histone H3 in tumors, confirming its functioning micro-tube protein targeting mechanism.
, SAR408701's overall toxicity in crab-eating monkeys was similar to that observed after simple intravenous DM4 injections.
based on this preclinical data, ADC SAR408701 is a promising potential therapeutic candidate for CEACAM5-positive tumors.
.